Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Immunotherapy × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hodgkin Disease 33 Melanoma 20 Lymphoma 8 Sarcoma 6 Neoplasm Metastasis 5 Leiomyosarcoma 3 Uveal Melanoma 2 Skin Neoplasms 2 Sarcoma, Synovial 2 Thyroid Neoplasms 1 Solitary Fibrous Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Neoplasms 1 Immunotherapy 1 Hyperthermia 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 Hemangioendothelioma 1 Gliosarcoma 1 Glioma, Subependymal 1 Glioma 1

Interventions

tremelimumab 1 olaparib 1 durvalumab 1 Immunotherapy, Adoptive 1 Dacarbazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04225390 2026-02-10

PROMIT

University of Erlangen-Nürnberg Medical School

Phase 2 Completed

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡